Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 4, 2018New England Journal of MedicineOpen Access

Chimeric Antigen Receptor Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

Carl H. June
Carl H. JuneUniversity of Maryland, BaltimoreMSMichel SadelainTongji University

Discussion

Loading...

Member takes

Implication

Review discusses chimeric antigen receptor therapy outcomes in treatment-resistant tumors, highlighting toxic effects.

Key Points

  • The review aims to explore the use of chimeric antigen receptor therapy in achieving long-term remissions in difficult-to-treat tumors.
  • Conducted an interview with Dr. Carl June to gather expert insights.
  • Reviewed literature on T-cell engineering and synthetic immunity.
  • Summarized toxic effects associated with chimeric antigen receptor therapies.
  • Chimeric antigen receptor therapy can produce durable remissions in refractory tumors.
  • The therapy is associated with toxic effects, including cytokine release syndrome and neurologic dysfunction.

Cite This Study

June et al. (2018) studied this question.

synapsesocial.com/papers/69d8d22b33ca018b39ae41eehttps://doi.org/10.1056/nejmra1706169
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X12008 · 1,871 citations
  2. 2CAR T cell immunotherapy for human cancer2018 · 3,271 citations
  3. 3Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia2018 · 5,841 citations
  4. 4Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia2014 · 2,520 citations
  5. 5Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy2009 · 320 citations